Arcus Biosciences RCUS Stock
Arcus Biosciences Price Chart
Arcus Biosciences RCUS Financial and Trading Overview
| Arcus Biosciences stock price | 23.86 USD |
| Previous Close | 25.34 USD |
| Open | 25.33 USD |
| Bid | 25.67 USD x 10000 |
| Ask | 25.72 USD x 20000 |
| Day's Range | 24.5 - 26.15 USD |
| 52 Week Range | 7.91 - 28.72 USD |
| Volume | 1.25M USD |
| Avg. Volume | 1.19M USD |
| Market Cap | 3.23B USD |
| Beta (5Y Monthly) | 0.874 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.17 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.82 USD |
RCUS Valuation Measures
| Enterprise Value | 2.48B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.21703 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.680495 |
| Price/Book (mrq) | 6.148503 |
| Enterprise Value/Revenue | 10.5 |
| Enterprise Value/EBITDA | -6.37 |
Trading Information
Arcus Biosciences Stock Price History
| Beta (5Y Monthly) | 0.874 |
| 52-Week Change | 174.83% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 28.72 USD |
| 52 Week Low | 7.91 USD |
| 50-Day Moving Average | 23.63 USD |
| 200-Day Moving Average | 20.01 USD |
RCUS Share Statistics
| Avg. Volume (3 month) | 1.19M USD |
| Avg. Daily Volume (10-Days) | 933.18K USD |
| Shares Outstanding | 125.77M |
| Float | 89.09M |
| Short Ratio | 8.33 |
| % Held by Insiders | 29.12% |
| % Held by Institutions | 72.47% |
| Shares Short | 10.89M |
| Short % of Float | 14.24% |
| Short % of Shares Outstanding | 8.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -156.35% |
| Operating Margin (ttm) | -788.23% |
| Gross Margin | -121.60% |
| EBITDA Margin | -164.83% |
Management Effectiveness
| Return on Assets (ttm) | -23.10% |
| Return on Equity (ttm) | -69.95% |
Income Statement
| Revenue (ttm) | 236M USD |
| Revenue Per Share (ttm) | 2.07 USD |
| Quarterly Revenue Growth (yoy) | -39.30% |
| Gross Profit (ttm) | -287000000 USD |
| EBITDA | -389000000 USD |
| Net Income Avi to Common (ttm) | -369000000 USD |
| Diluted EPS (ttm) | -3.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 822M USD |
| Total Cash Per Share (mrq) | 6.54 USD |
| Total Debt (mrq) | 113M USD |
| Total Debt/Equity (mrq) | 21.57 USD |
| Current Ratio (mrq) | 4.038 |
| Book Value Per Share (mrq) | 4.175 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -488000000 USD |
| Levered Free Cash Flow (ttm) | -156000000 USD |
Profile of Arcus Biosciences
| Country | United States |
| State | CA |
| City | Hayward |
| Address | 3928 Point Eden Way |
| ZIP | 94545 |
| Phone | 510 694 6200 |
| Website | https://arcusbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 601 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Q&A For Arcus Biosciences Stock
What is a current RCUS stock price?
Arcus Biosciences RCUS stock price today per share is 23.86 USD.
How to purchase Arcus Biosciences stock?
You can buy RCUS shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arcus Biosciences?
The stock symbol or ticker of Arcus Biosciences is RCUS.
Which industry does the Arcus Biosciences company belong to?
The Arcus Biosciences industry is Biotechnology.
How many shares does Arcus Biosciences have in circulation?
The max supply of Arcus Biosciences shares is 125.77M.
What is Arcus Biosciences Price to Earnings Ratio (PE Ratio)?
Arcus Biosciences PE Ratio is now.
What was Arcus Biosciences earnings per share over the trailing 12 months (TTM)?
Arcus Biosciences EPS is -3.17 USD over the trailing 12 months.
Which sector does the Arcus Biosciences company belong to?
The Arcus Biosciences sector is Healthcare.
Arcus Biosciences RCUS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NYSE Composite Index NYA | 23276.49 USD — |
-0.87
|
— — | — — | — — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
- {{ link.label }} {{link}}